Mobile Menu

Liquid Biopsy ONLINE

When: May 16, 2024 Time: 3:00 pm

Liquid biopsy offers a non-invasive, easily administered, alternative to molecular profiling from tissue. This means we can monitor cancer development and progression in real-time. However, before consolidating such methods in the clinic, we must establish the right biomarkers, technologies and develop standardised clinical procedures. 

Our new webinar series – Liquid Biopsy ONLINE – is your chance to hear from a variety of experts on the latest methods, technologies and clinical applications for liquid biopsy all in one place! 

Furthermore, the field is constantly changing, and this webinar series provides the latest updates and insights which can’t be obtained from review papers.  

In this webinar, we will cover how the field is moving across the whole liquid biopsy pipeline – from research and developments, through to clinical application and producing tangible patient benefit. We’ll review the different biomarkers being studied, their applications in clinical practice and utility of liquid biopsy in early cancer detection.   

This Liquid Biopsy ONLINE webinar series will provide you with:  

  • A spotlight on how the latest highly sensitive liquid biopsy assays are providing new opportunities for early cancer screening and surveillance. 
  • Multiple examples of how researchers are exploring a multi analyte approach to liquid biopsy and the new opportunities arising from using a diverse range of analytes outside the realms of ctDNA, such as EVs, RNA and CTCs. 
  • Talks and Q&A sessions from 10 expert speakers, with representation across sectors – academia, pharma, healthcare and industry. 

This series will be held on 16th, 23rd and 30th May 2024 at 3pm BST / 4pm CET / 10am EDT.  

 **Please note that by registering for one webinar in the series, you will automatically be registered to all subsequent webinars**  

Webinar 1: Using Liquid Biopsies to Advance Treatment Selection and Monitoring 

Thursday 16th May at 3pm BST / 4pm CEST / 10am EDT  

 Webinar one will cover how liquid biopsies, and particularly ctDNA monitoring, can be used to determine the clinical efficacy of cancer drugs. This includes using ctDNA for treatment selection and early decision making for cancer drugs in phase one studies, for disease monitoring and for getting the right treatment to the right patient in the context of cancers such as triple negative breast cancer. 

Talk 1: Using ctDNA Monitoring in Clinical Trials and Drug Development 

  • Qu Zhang, Scientific Director, Precision Medicine Solid Tumour, AbbVie 

Talk 2: From Research To Clinic: The Role of Automation in Liquid Biopsies

  • Philipp Ott, Head Rapid Design and Innovation, Tecan 

Talk 3: ctDNA in the Clinical Setting for Triple Negative Breast Cancer 

  • Marla Lipsyc-Sharf, MD, Clinical Instructor of Medicine, UCLA Health 

Talk 3: Clinical Implications of Liquid Biopsy Testing in Paediatric Solid Tumours 

  • Brian Crompton, MD, Research Co-Director, Solid Tumor Center, Dana Farber Cancer Institute  

Webinar 2: Exploring New Biomarkers and Detection Targets  

  Thursday 23rd May at 3pm BST / 4pm CEST / 10am EDT  

In recent years, scientists have primarily focussed on detecting ctDNA and CTCs from liquid biopsies. However, both have their own unique challenges and scientists are now looking to standardise these existing biomarkers and increase the number of targets at their disposal. Webinar Two will present some of the latest biomarkers being studied for a multi-analyte and multi-modal liquid biopsy approach. This includes developing microRNAs signatures in pancreatic cancer, isolating better EV-miRNAs to improve the diagnostic performance of circulating miRNAs and the recommended clinical practices for CTCs. 

Talk 1: Translational Studies for MicroRNA-Based Blood Diagnostics for Sensitive and Specific Monitoring of Therapy Successes for Pancreas Cancer and Glioblastoma

  • Ulf Kahlert, Professor, Otto-von-Guericke University Magdeburg  

Talk 2: Harnessing Cancer-Derived, miRNA-Enriched Extracellular Vesicles for Liquid Biopsy 

  • Honami Naora, Professor, MD Anderson Cancer Center  

Talk 3: Characterisation of CTCs and Recommendation in Clinical Practice 

  • María Jose Serrano, Head of Liquid Biopsy and Cancer Interception Group, Genyo  

Webinar 3: Liquid Biopsies for Early Cancer Detection and Surveillance  

  Thursday 30th May at 3pm BST / 4pm CEST / 10am EDT  

 Webinar Three will cover the latest methods that are being employed to improve the utility of liquid biopsies for early cancer screening and disease monitoring. This includes blood-based colorectal cancer screening tests, molecular residual disease testing and using the combination of genetic and epigenetic information in cell-free DNA for greater power in detecting disease associations. 

Talk 1: Emerging Tests for Non-invasive Colorectal Cancer Screening   

  • William Grady, MD, Professor, Translational Science and Therapeutics Division; Medical Director, GI Cancer Prevention Program, Fred Hutchinson Cancer Center  

Talk 2: More Information From Limited DNA: Simultaneous Measurement of Genetics, 5hmC and 5mC in Cell-Free DNA  

  • Tom Charlesworth, Director, Market Strategy and Corporate Development, biomodal 

Talk 3: New Opportunities for Liquid Biopsy-based Hereditary Cancer Surveillance  

  • Trevor Pugh, Senior Investigator and Director, Genomics, Ontario Institute for Cancer Research  

Talk 4: Molecular Residual Disease in Breast Cancer: Clinical Landscape & Therapeutic Opportunities 

  • Arielle Medford, Medical Oncologist, Mass General Cancer Center  


Article Search